Using AI to fight COVID-19 may harm disadvantaged groups, experts say

[ad_1]

Read More/Less


The university’s researchers also highlighted discrimination in AI technology as they pick symptom profiles from medical records, reflecting and exacerbating biases against minorities

(Subscribe to our Today’s Cache newsletter for a quick snapshot of top 5 tech stories. Click here to subscribe for free.)

Companies worldwide have devised methods in the past year to harness the power of big data and machine learning (ML) in medicine. A model developed by Massachusetts Institute of Technology (MIT) uses AI to detect asymptomatic COVID-19 patients through coughs recorded on their smartphones. In South Korea, a company used cloud computing to scan chest X-rays to monitor infected patients.

Artificial intelligence (AI) and ML have been extensively deployed during the pandemic, and their use ranged from data extraction to vaccine distribution. But experts from the University of Cambridge raise questions on ethical use of AI as they see the technology to have a tendency to harm minorities and those from lower socio-economic status.

“Relaxing ethical requirements in a crisis could have unintended harmful consequences that last well beyond the life of the pandemic,” said Stephen Cave, Director of Cambridge’s Center for the Future of Intelligence (CFI).

Also Read | Competition between prediction algorithms is bad for customers, study finds

Making clinical choices like predicting deterioration rates of patients who may need ventilation can be flawed as the AI model uses biased data. These trained datasets and algorithms are inevitably skewed against groups that access health services infrequently, including minority ethnic communities and those belonging to lower social status, Cambridge team warned.

Another issue is in the way algorithms are used to allocate vaccines locally, nationally and globally. Last December, Stanford Medical Centre’s vaccination plan algorithm left out several young front-line workers.

“In many cases, AI plays a central role in determining who is best placed to survive the pandemic. In a health crisis of this magnitude, the stakes for fairness and equity are extremely high,” said Alexa Hagerty, research associate at University of Cambridge.

Also Read | How bias crept into AI-powered technologies

The university’s researchers also highlighted discrimination in AI technology as they pick symptom profiles from medical records, reflecting and exacerbating biases against minorities.

The use of contact-tracing apps has also been criticised by several experts around the world, stating that it excludes those who don’t have access to the internet and those who lack digital skills, among other user privacy issues.

In India, biometric identity programmes can be linked to vaccination distribution, raising concerns for data privacy and security. Other vaccine allocation algorithms, including some used by the COVAX alliance, are driven by privately owned AI. These private algorithms are like ‘black box’, Hagerty noted.

[ad_2]

READ FULL ARTICLE HERE

81% Interim Efficacy Data Shot in the Arm for Bharat Biotech’s Covaxin Export Hopes

[ad_1]

Read More/Less


The first interim review of Phase-3 trials for Bharat Biotech’s COVID-19 vaccine Covaxin revealed 81 percent efficacy, providing a boost to the Indian business, which is eyeing exports and hopes to join the World Health Organization’s COVAX program for vaccination in low- and middle-income countries.

The first interim study is focused on 43 cases, with 36 cases of COVID-19 in the placebo group versus 7 cases in the Covaxin group, yielding an 80.6 percent point estimate of vaccine efficacy.

In the coming weeks, the Hyderabad-based firm said it would share the second interim analysis based on 87 cases, as well as the final analysis based on 130 cases. This will provide a more complete image of the vaccine’s efficacy.

Bharat Biotech Chairman and Managing Director Krishna Ella had recently said he wanted the firm to be part of the COVAX Facility. In the next three months, the COVAX program has committed to supplying 237 million doses of AstraZeneca’s vaccine to 142 countries.

Bharat Biotech has begun to sign bilateral supply agreements for Covaxin. It announced on February 26 that it had signed a deal with Brazil to supply 20 million doses of its COVID-19 vaccine Covaxin. The deliveries are scheduled to start in the second and third quarters of 2021, but a lack of efficacy data has been a stumbling block, said a report in Moneycontrol. Reuters had reported that Brazilian prosecutors have sought immediate suspension of purchases of India’s Covaxin as the vaccine didn’t have phase-3 efficacy data.

Meanwhile, France is also looking to import Covaxin, Moneycontrol had reported. Covaxin has piqued the attention of more than 40 countries around the world, according to Bharat Biotech. “These countries are highly satisfied with the safe, inactivated vaccine technology and robust data package for safety and immunogenicity,” the firm said.

Covaxin also has a time-tested inactivated platform that has been shown to be successful against mutating strains. Unlike other vaccines that use one of the virus’s most prominent proteins as an antigen, which is susceptible to losing effectiveness if the virus mutates, this one does not. Inactivated vaccines use whole virion, which is more durable and provides a wider range of protection.

Covaxin is also stable at 2 to 8°C (refrigerated) and comes in a ready-to-use liquid formulation, allowing it to be distributed across existing vaccine supply chains.

The company also claims to have a 28-day open vial policy as a unique product feature, which it claims reduces vaccine wastage by 10-30%.

Furthermore, Covaxin has had the government’s full support from the start. Despite criticism that it lacked efficacy evidence, the vaccine was approved for limited emergency use in clinical trial mode in January. Modi’s Atmanirbhar has highlighted Covaxin as a success story.



[ad_2]

READ FULL ARTICLE HERE